Canadian Intellectual Property Office

IGC Pharma Reports Second Quarter Fiscal 2024 Results

Retrieved on: 
Monday, November 13, 2023

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the second fiscal quarter of 2024 ended September 30, 2023 (Q2 FY2024).

Key Points: 
  • IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the second fiscal quarter of 2024 ended September 30, 2023 (Q2 FY2024).
  • Revenue in Q2 FY2024 increased 44% to approximately $291,000 compared to the same quarter in FY2023 at roughly $202,000.
  • In the first six months of FY2024, revenue doubled to about $846,000 from about $414,000 compared to the prior year’s six-month period.
  • The Company continues to drive progress with ten sites in the United States and Canada, currently conducting the trial.

EQS-News: DEFENCE THERAPEUTICS KEY PLATFORM PATENT ACCEPTED BROADLY COVERING VACCINE TECHNOLOGY

Retrieved on: 
Tuesday, November 7, 2023

3,201,103 (the ‘103 patent) broadly covers Defence’s key vaccine platform technologies that dramatically enhances the immunogenicity of protein subunit vaccines, improving their efficacy and potentially lowering antigen dose required to elicit a protective immune response.

Key Points: 
  • 3,201,103 (the ‘103 patent) broadly covers Defence’s key vaccine platform technologies that dramatically enhances the immunogenicity of protein subunit vaccines, improving their efficacy and potentially lowering antigen dose required to elicit a protective immune response.
  • This Canadian patent includes important composition of matter claims that directly cover any protein subunit vaccine employing Defence’s technology, as well as claims covering their manufacture and use to fight cancer and infectious diseases.
  • The issuance of the ‘103 patent bolsters Defence’s domestic patent portfolio and aligns with the Company’s objectives to advance their own novel clinical vaccine candidates.
  • Rising concern about the cancer and patient is one of the major factors driving the market for the oncology market.

MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

Retrieved on: 
Wednesday, October 11, 2023

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than November 2035.

Key Points: 
  • Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than November 2035.
  • The allowed claims cover a wide range of doses and a range of dosing regimens for both MN-166 (ibudilast) and riluzole.
  • Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc., commented, "We are very pleased to receive notice that this new patent will be granted.
  • The U.S. FDA granted both orphan-drug designation and fast-track designation to MN-166 for the treatment of ALS, and the European Commission granted Orphan Medicinal Product Designation to MN-166 for the treatment of ALS."

Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants

Retrieved on: 
Monday, October 2, 2023

FLORHAM PARK, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced significant advancements to its global intellectual property (IP) portfolio.

Key Points: 
  • FLORHAM PARK, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced significant advancements to its global intellectual property (IP) portfolio.
  • This patent significantly enhances the use of iopofosine I 131 for treating various cancers, including gliomas, lung cancer, melanoma, and more, with a focus on cancer stem cells.
  • The Canadian Intellectual Property Office (CIPO), the Australian Patent Office (IP Australia) and the EPO have granted patent number 17814042.2 for "Phospholipid Ether Analogs for the Identification and Isolation of Circulating Tumor Cells".
  • “The expanded protection in these key global regions supplements our existing patent portfolio and the coverage with these patents we have already obtained in the US and other territories.

MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe

Retrieved on: 
Wednesday, August 16, 2023

This patent is expected to expire no earlier than June 2035.

Key Points: 
  • This patent is expected to expire no earlier than June 2035.
  • The allowed claims cover the use of MN-001 (tipelukast) for inhibiting or treating scleroderma and/or systemic sclerosis.
  • Ph.D., MPH., Chief Medical Officer, MediciNova, Inc., commented, “This new patent is based on positive results from a systemic sclerosis animal model study conducted recently.
  • We are very pleased to receive notice of this new patent which covers Europe, and we believe it could increase the potential value of MN-001.”

60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects

Retrieved on: 
Monday, July 31, 2023

Tafenoquine is the active molecule in 60 Degrees Pharmaceuticals’ USFDA-approved drug for malaria prevention, ARAKODA®.

Key Points: 
  • Tafenoquine is the active molecule in 60 Degrees Pharmaceuticals’ USFDA-approved drug for malaria prevention, ARAKODA®.
  • There are no vaccines approved to prevent malaria in malaria-naïve travelers so public health agencies recommend the use of malaria chemoprophylactic drugs.
  • The newly issued Canadian patent provides exclusive use of tafenoquine for preventing malaria in malaria-naive patients in Canada to December 2, 2035.
  • The Company was previously issued a U.S. patent covering the use of tafenoquine for malaria prevention in malaria-naïve individuals.

Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease

Retrieved on: 
Thursday, July 13, 2023

AV-101 is the Company’s oral prodrug antagonist at the NMDAR (N-methyl-D-aspartate receptor) glycine site.

Key Points: 
  • AV-101 is the Company’s oral prodrug antagonist at the NMDAR (N-methyl-D-aspartate receptor) glycine site.
  • The patent, once granted, will not expire until at least 2034.
  • The U.S. Patent and Trademark Office (USPTO) granted a related U.S. patent for Vistagen’s AV-101 and similar patents have been granted or are pending in several additional major pharmaceutical markets.
  • The study demonstrated that AV-101 significantly (p = 0.01) reduced LID without affecting the timing, extent, or duration of the therapeutic benefits of L-Dopa.

Anixa Biosciences Announces Issuance of Canadian Patent for its CAR-T Cancer Therapy Technology

Retrieved on: 
Tuesday, July 11, 2023

SAN JOSE, Calif., July 11, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office has issued Canadian Patent 2,989,807 covering Anixa's novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology, which has been licensed from The Wistar Institute and is being developed in partnership with Moffitt Cancer Center.  

Key Points: 
  • SAN JOSE, Calif., July 11, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office has issued Canadian Patent 2,989,807 covering Anixa's novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology, which has been licensed from The Wistar Institute and is being developed in partnership with Moffitt Cancer Center.
  • The patent, entitled "Methods and Compositions for Treating Cancer," covers a nucleic acid that encodes a chimeric protein whose domains can be used to treat certain types of cancer by binding to specific hormone receptors and activating T cells.
  • The patent was invented by Drs.
  • Jose Conejo-Garcia and Alfredo Perales-Puchalt, both formerly of The Wistar Institute, to which the patent is assigned, along with Anixa's majority-owned subsidiary, Certainty Therapeutics, Inc., which is the exclusive, world-wide licensee.

PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301

Retrieved on: 
Tuesday, July 11, 2023

The intellectual property provides broad protection for treatments utilizing Versamune® based therapies, including PDS0101, in combination with PDS0301 as a potential treatment for cancer.

Key Points: 
  • The intellectual property provides broad protection for treatments utilizing Versamune® based therapies, including PDS0101, in combination with PDS0301 as a potential treatment for cancer.
  • This patent expands PDS Biotech’s market coverage and adds to the world-wide patent portfolio including the patent granted by the United States Patent and Trademark Office (USPTO), U.S. Patent No.
  • “This newly allowed patent adds to the intellectual property governing Versamune® based therapies in combination with PDS0301, which we believe represent a potentially transformative treatment approach for advanced cancer patients,” said Dr. Frank Bedu-Addo, CEO of PDS Biotech.
  • PDS Biotech’s exclusive rights to the combination of PDS0101 and PDS0301 permits it to design compositions and methods that overcome tumor immune suppression utilizing a different mechanism from checkpoint inhibitors.

Propanc Biopharma Provides Shareholder Update

Retrieved on: 
Thursday, June 22, 2023

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced a shareholder update including recent developments and forecast for 2023/24, as Propanc prepares to file a Form 10-K annual report, whose fiscal year end is June 30.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced a shareholder update including recent developments and forecast for 2023/24, as Propanc prepares to file a Form 10-K annual report, whose fiscal year end is June 30.
  • Propanc recently filed a post-effective Form S-1 amendment on behalf the lead investor who has funded approximately $2.25 million to date.
  • Propanc plans to compile the Investigational Medicinal Product Dossier, study proposal and Investigator’s Brochure in 2023.
  • To date, Propanc has raised approximately $23 million dollars, culminating in the Company’s lead asset ready to commence clinical development, and a backup clinical compound entering preclinical stage.